Interferone LAMBDA: Bristol-Myers Squibb blocca la fase di ricerca

Considerato il rapidissimo sviluppo di terapie efficacissime con regimi orali per la cura dell’epatite C, anche in pazienti difficili da curare, Bristol-Myers Squibb ha deciso di bloccare in via definitiva lo sviluppo del proprio interferone LAMBDA che era giunto alla fase III. Tutti gli studi in corso saranno comunque regolarmente completati.

Di seguito una breve nota.

La redazione di EpaC onlus

Bristol-Myers Squibb has recently reviewed its hepatitis C (HCV) pipeline, and as a result has decided to halt development of Lambda, an investigational type III lambda interferon that was being studied as a potential alternative to alfa-interferon. The rapidly evolving HCV treatment landscape has seen major progress during the last year with the regulatory submissions and approvals of multiple, all oral, treatment regimens. While there are still unmet needs today for some patient types, especially those with cirrhosis and advanced liver disease, emerging data on upcoming regimens indicate that even hard-to-treat patients may be able to achieve cure with an all-oral regimen, diminishing the need for a new type of interferon.

BMS thanks those members of the HCV community who have participated in the endeavor to evaluate the potential of Lambda. We remain committed to the patients and investigators participating in the ongoing Lambda trials, and will continue the Lambda trials through an appropriate endpoint, which is generally SVR12 (sustained virologic response 12 weeks after the end of treatment; the recognized endpoint assessing viral cure).

BMS remains committed to HCV and our late-stage HCV DAA development program remains unaffected.